WALTHAM, Mass., May 15 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. announced today that it will be presenting at the BIO 2009 Business Forum on Wednesday, May 20, 2009, at 2:40 p.m. EDT in Room 313 at the Sheraton Atlanta Hotel in Atlanta, GA. Lewis H. Bender, Chief Executive Officer, will present an overview of Interleukin Genetics to include the Company's business model, available genetic tests and recent milestones.
"Genetic testing and personalized medicine offer a significant opportunity, with the potential to help drug makers improve the success of their therapies and enable individuals to make more informed lifestyle choices to improve their health," Mr. Bender said.
The BIO International Convention is the world's largest gathering of the biotechnology industry, being held this year in Atlanta, GA, from May 18-21st.
About BIO
The Biotechnology Industry Organization (BIO) represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
About Interleukin Genetics
Interleukin Genetics, Inc. , is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.
CONTACT: Media: Erin Walsh, Interleukin Genetics, +1-781-419-4707,
ewalsh@ilgenetics.com; Investor Relations: Melanie Friedman, Stern Investor
Relations, +1-212-362-1200, Melanie@sternir.com
Web site: http://www.ilgenetics.com/
